Sterile injectable drugs are drug preparations containing active ingredients, which are injected into the body using syringes or needles. The drug and its preparations are available in sterile forms and are safe and effective for the treatment of diseases showing a low response to oral medications. These drugs assist in faster recovery from disease and can be used as an alternative in hospitals to conventional methods. Market Industry Reports (MIR) has published a new report titled “Sterile Injectable Drugs Market -Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2030.” According to the report, the sterile injectable drugs market is estimated to be over US$ 500.0 billion in 2019. It is anticipated to grow at a double-digit CAGR from 2019 to 2030.
The continual growth of the sterile injectable drugs market can be attributed to several factors that have led to the wide-scale adoption of these drugs for treatment and speedy recovery. Moreover, the growing demand for these drugs for the treatment of chronic disease across the globe is anticipated to further contribute to the substantial growth during 2019 and 2030. To obtain better insights into the market scenario, prominent players are increasingly focusing on collaborative initiatives. In 2015, Pfizer acquired Hospira, a provider of infusion technologies, injectable drugs, and biosimilars. In 2018, Endo acquired Somerset Therapeutics, a developer and marketer of ophthalmic drug sterile injectable.
Major Key Players of the Sterile Injectable Drugs Market are:
Johnson & Johnson Services, Sanofi, Novo Nordisk A/S, Pfizer, AstraZeneca, Merck & Co., Johnson & Johnson Services, GlaxoSmithKline plc., Gilead Sciences, Inc. Baxter, and others.
Johnson & Johnson Services, Sanofi, Novo Nordisk A/S, Pfizer, AstraZeneca, Merck & Co., Johnson & Johnson Services, GlaxoSmithKline plc., Gilead Sciences, Inc. Baxter, and others.
No comments:
Post a Comment